A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.

Summary

A Randomized, Double Blind, Placebo Controlled, Phase 2 Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple I.V. Doses of SLV334 in Sequential Cohorts of Patients with Moderate and Severe Traumatic Brain Injury.

Timeline

Start

2009-04

Primary completion

2010-08

Completion

2010-08

Outcome

Outcome not reported

Stopped (Business): “This study was stopped 20 May 2010 due to strategic considerations”

Drugs

Indications